Peptides Are the New Wellness Cure-All (NY Mag, Jan. 27, 2026) examines the surging trend of peptides as DIY injectables for energy, fat loss, muscle gain, skin improvement, injury healing, libido, and anti-aging.
Key Drivers and Appeal
Fueled by GLP-1 drugs (Ozempic/Wegovy) normalizing self-injection, social media (Instagram/TikTok/Discord/Reddit), looksmaxxing culture, and influencers. Users and the author (who tried NAD+ and felt mild euphoria/alertness) report transformative benefits like sustained energy, better recovery, glowing skin, and resolved chronic issues. Many stack compounds (e.g., BPC-157/TB-500 for healing, retatrutide for weight loss, GHK-Cu for skin).
Supply and Market
Gray market boom: US compounding pharmacies/clinics (expensive) vs. cheap direct-from-China factories (vials often 10x cheaper; e.g., $20 vs. $400+). Sold “for research only” via WhatsApp/Instagram ads (often AI avatars), with bulk shipping.
Resellers, clinics, and influencers profit via arbitrage. Some users test batches independently. Ties into broader biohacking and post-GLP-1 normalization.
Culture and Risks
Widespread among bodybuilders, fitness enthusiasts, LA/Miami scenes, and even teens. Looksmaxxing pushes extreme optimization (“ascending,” mogging).
Downsides: FDA concerns (bans on several compounds since 2023 for safety/efficacy issues); contamination, misdosing, degradation common in untested Chinese products (~30% failure rate in independent tests). Reported harms include pancreatitis, nerve pain, hospitalizations. Long-term data lacking; relies on anecdotes.
The article balances fascination with the accessibility and reported results against regulatory gaps, quality risks, influencer grift, and the high-stakes self-experimentation trend—positioning peptides as a cultural phenomenon with significant upside claims but real dangers. The author experiments personally, highlighting the temptation.
Cjc is too big to be absorbed by the nose, and will be degraded by the nasal mucosa anyway. Ipamorelin can get through, but you’ll probably need more than from an injection to overcome degradation. Nasal spray for these seems like a waste overall.
Same issue with high molecular weight and mucosal degradation. Pharmacies probably put some stuff to try to enhance absorption, but you’re still better off injecting if you can.
“Researchers from the Keck School of Medicine of USC have now identified the thymus, a small organ behind the breastbone that plays a central role in immune system development, as a key player in inflammaging. They discovered that thymulin, a hormone produced by the organ, keeps inflammation under control. As we age, thymulin decreases and inflammation increases, allowing diseases like cancer to progress. In older mice, increasing thymulin levels improved cancer survival and made immunotherapy more effective. The study, funded by the National Institutes of Health, was just published in Nature Communications.”
Note this is thymulin NOT thymogen (thymogen is one of the sketchy “bioregulators” out of Russia).
I have not spent any time researching this on my own yet, but I’m assuming this is TA-1, correct? Or is this a different available peptide?
Yesterday, my friend’s cat was just diagnosed with carcinoma (in he nasal cavity making surgical treatment for a 12 yo cat too risky, not to mention she was quoted 25k for radiation that doesn’t have a great prognosis either). Yesterday her cat was put on immunotherapy and steroids.
Any thoughts about if TA-1 might be an appropriate experiment for a cat? I realize nothing will cure her but I’m grasping at straws if there is something that might just make the time she has left a little more comfortable and longer? She has a lot of quality of life right now but apparently that will change pretty quickly
Not approved yet. It’s just a committee voting now. They will provide their opinions to the FDA and later this year, the FDA will make the final ruling and just as easily choose no to all.
Popular gray-market drugs may soon be easy to get through mainstream channels.
BPC-157 is rumored to heal almost anything: a sore shoulder, a bum knee, a pulled hamstring, ulcerative colitis. Maybe even traumatic brain injuries and multiple sclerosis, too. The drug—part of a class called peptides—has been around for decades. But it has recently experienced a surge in popularity, thanks in part to great peptide publicity from influencers, podcasters, and Robert F. Kennedy Jr., the secretary of health and human services. Thousands of Americans are taking it. And almost all of them are sourcing it from sketchy online vendors, many of which are supplied by manufacturers in China.
But BPC-157 may soon become easier to obtain through more reputable channels. An advisory committee to the Food and Drug Administration voted yesterday to recommend that compounding pharmacies be allowed to make the peptide, even though it has little human-safety data and hasn’t passed through the normal FDA drug-approval process. For BPC-157 enthusiasts—and they seem to be legion—it’s welcome news. For telehealth companies, it might mark the beginning of a peptide gold rush.
Before yesterday’s vote, the prospects for BPC-157 appeared bleak. At the meeting of the Pharmacy Compounding Advisory Committee—which last month added eight new members, many with ties to telehealth companies and wellness clinics—FDA researchers argued that the scientific evidence supporting BPC-157 was weak. They insisted there weren’t enough data to be sure that BPC-157 is safe, that it works, or even which sequence of amino acids it necessarily contains. As one FDA official put it: “We don’t actually know with any certainty what it is.”
This is not an “approval” process. The end result is removing the restriction and allowing these peptides to be processed and sold by compounding pharmacies.
For a drug/peptide to be approved takes years of clinical studies to establish efficacy and most importantly safety in humans. This is not what is happening.
With no proof of efficacy or safety in humans, there is no way that they will be covered by any health care/insurance system. I’d be surprised if very many Dr’s will jump on this bandwagon as the US is a very litigious place for health care providers. We were sued 3 times as a mfg of medical devices in the US, we won all three suits
Category 2 “restricted” peptides
Category 2 of the “Bulk Drug Substances Nominated Under Sections 503A or 503B” list identifies substances that “may present significant safety risks” and therefore are generally not eligible for routine compounding; multiple peptides were placed here in 2023.fda+2
This Category 2 placement is an FDA policy action under its 503A/503B authority; it does not create a separate criminal statute, but it effectively prohibits 503A/503B facilities from compounding these peptides, making their pharmacy supply chain illegal if compounded.fda+2
Examples include BPC‑157, TB‑500, CJC‑1295 and others that were moved into Category 2, though HHS has since announced that many of these will be shifted back to Category 1, restoring compounding eligibility
Your confused, the OP’s article was about ‘Approved for Compounding’.
My reply was to this, No one said anything about ‘Approving’ as a drug.
The point was the committee’s votes still do not authorize compounding, the FDA will review the committees findings in months or even years and only then will they become legal for compounding.
I’m not actually confused on my point, I can see that my post was confusing though and your point I agree on and is accurate
The consumer is confused and the vendors will support that confusion by intimating these peptides are “FDA approved”, leading people to think that’s true.
This will be an uncorrectable confusion in the market place
